A Phase 3 interventional study of Brolucizumab 6 mg and Panretinal photocoagulation laser in Proliferative Diabetic Retinopathy, sponsored by Novartis Pharmaceuticals. Completed at 120 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals · Phase 3, Interventional, and Treatment
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.
Phase III, 96-week, two-arm, randomized (1:1 ratio), single-masked, multi-center, active-controlled study to evaluate the efficacy and safety of brolucizumab compared to Panretinal photocoagulation (PRP) in subjects with Proliferative diabetic retinopathy (PDR).
Subjects who consented underwent screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria. Subjects who met all the inclusion and none of the exclusion criteria were randomized in a 1:1 ratio to one of the following treatments:
Brolucizumab 6 mg: 3 x q6w loading then q12w maintenance through Week 90, with the option from Week 48 onwards to extend the treatment interval by 6 weeks at a time up to 24 weeks, and revert to q12w if disease worsens. More frequent injection with q6w interval in the maintenance phase could be administered at the discretion of the Investigator if the disease worsens.
PRP: initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment (may split into 2-4 sessions) as needed up to Week 90.
Visits occurred every 6 weeks throughout the study, regardless of treatment or not.
23 studies on the registry are indexed under Retinal Neovascularization; 2 are open to participants now.
This study's enrollment of 689 is above the median of 40 across 14 interventional studies indexed under Retinal Neovascularization.
Browse Retinal Neovascularization studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Intra-vitreal injection. 3 x q6w loading injections, followed by q12w maintenance through Week 90
Biological: Brolucizumab 6 mg
Initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
Procedure: Panretinal photocoagulation laser
3 x q6w loading injections, followed by q12w maintenance through Week 90
Also known as: RTH258
initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
Also known as: PRP
Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of \>= 34 ETDRS letters (Snellen equivalent 20/200) at Screening / Baseline in the study eye were included. Min and max possible scores are 0-100 respectively. A higher score represents better functioning. Last observation carried forward (LOCF) was used for the imputation of missing values.
Time frame: Baseline, Week 54
Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 54 for the Study Eye
Proliferative diabetic retinopathy (PDR) is derived from the diabetic retinopathy severity scale (DRSS) as assessed by the central reading center (CRC) using 7-field color fundus photography image. The DRSS on the original score with scores varying from 10 (DR absent) to 85 (very advanced PDR) were then converted into a 12-level scale (Range is from 1 - diabetic retinopathy (DR) absent, to 12- very advanced PDR). (A lower score represents a better outcome.) The event of "No PDR" is then defined as DRSS (12-level scale) \< 7.
Time frame: Week 54
Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 96 for the Study Eye
Proliferative diabetic retinopathy (PDR) is derived from the diabetic retinopathy severity scale (DRSS) as assessed by the central reading center (CRC) using 7-field color fundus photography image. The DRSS on the original score with scores varying from 10 (DR absent) to 85 (very advanced PDR) were then converted into a 12-level scale (Range is from 1 - diabetic retinopathy (DR) absent, to 12- very advanced PDR). (A lower score represents a better outcome.) The event of "No PDR" is then defined as DRSS (12-level scale) \< 7.
Time frame: Week 96
Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 54 for the Study Eye
Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center. PRP = Panretinal photocoagulation laser
Time frame: Up to Week 54
Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 96 for the Study Eye
Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center. PRP = Panretinal photocoagulation laser
Time frame: Up to Week 96
Area Under the Curve in Change From Baseline in BCVA up to Week 54 and up to Week 96 - for the Study Eye
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of \>= 34 ETDRS letters (Snellen equivalent 20/200) at Screening / Baseline in the study eye were included. Min and max possible scores are 0-100 respectively. A higher score represents better functioning. Last observation carried forward (LOCF) was used for the imputation of missing values. The AUC in change from Baseline in BCVA up to Week 54 (or Week 96) is referred to as the averaged change from Baseline in BCVA at each visit up to 54 (or Week 96), which was calculated as (BCVA at Week 6 + BCVA at Week 12 + ... + BCVA at Week 54 (or Week 96)) / number of visits with valid BCVA data from Week 6 to Week 54 (or Week 96) - BCVA at Baseline.
Time frame: Baseline, up to Week 54 and up to Week 96
Diabetic Retinopathy Severity Scale (DRSS): Number and Percentage of Subjects With ≥2 Steps Improvement From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) DRSS Score at Week 54 and Week 96
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
Time frame: Baseline, Week 54 and Week 96
Diabetic Retinopathy Severity Scale (DRSS): Number and Percentage of Subjects With ≥2 Steps Worsening From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) DRSS Score at Week 54 and Week 96
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
Time frame: Baseline, Week 54 and Week 96
Diabetic Retinopathy Severity Scale (DRSS): Number and Percentage of Subjects With ≥3 Steps Improvement From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) DRSS Score at Week 54 and Week 96
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
Time frame: Baseline, Week 54 and Week 96
Diabetic Retinopathy Severity Scale (DRSS): Number and Percentage of Subjects With ≥3 Steps Worsening From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) DRSS Score at Week 54 and Week 96
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
Time frame: Baseline, Week 54 and Week 96
Number and Percentage of Subjects Developing Vision-threatening Complications Associated With Diabetic Retinopathy up to Week 54 and up to Week 96
The vision-threatening complications associated with Diabetic retinopathy (DR) are defined as any event of the following list occurring in the study eye at any time point after Baseline: * Center-involved Diabetic macular edema (CI-DME) as defined as Central sub-field thickness (CSFT) ≥280 µm according to Central reading center (CRC) evaluation of Optical coherent tomography (OCT) image * Retinal detachment * Vitreous hemorrhage * Neovascular glaucoma, iris/ anterior chamber angle neovascularization * Vitrectomy for DR complications
Time frame: up to Week 54 and up to Week 96
Ocular AEs (>= 2% in Any Treatment Arm) by Preferred Term for the Study Eye
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. AEs that started after alternative diabetic retinopathy treatment/relevant diabetic macular edema treatment in the study eye are censored.
Time frame: Adverse events are reported from first dose of study treatment up to Week 90, plus approximately 6 weeks post-treatment, up to a maximum timeframe of approximately 96 weeks.
Non-ocular AEs (≥ 2% in Any Treatment Arm) by Preferred Term
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. AEs that started after alternative diabetic retinopathy treatment/relevant diabetic macular edema treatment in the study eye are censored.
Time frame: Adverse events are reported from first dose of study treatment up to Week 90, plus approximately 6 weeks post-treatment, up to a maximum timeframe of approximately 96 weeks.
| Milestone | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Started | 347 | 342 |
| Completed | 301 | 287 |
| Not completed | 46 | 55 |
| Withdrew: Withdrawal by subject | 20 | 20 |
| Withdrew: Progressive disease | 0 | 2 |
| Withdrew: Physician decision | 4 | 6 |
| Withdrew: Lost to follow-up | 11 | 13 |
| Withdrew: Death | 8 | 9 |
| Withdrew: Adverse event | 3 | 5 |
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of \>= 34 ETDRS letters (Snellen equivalent 20/200) at Screening / Baseline in the study eye were included. Min and max possible scores are 0-100 respectively. A higher score represents better functioning. Last observation carried forward (LOCF) was used for the imputation of missing values.
| Letters Read | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye | 0.2 ± 0.72 | -4.2 ± 0.73 |
Proliferative diabetic retinopathy (PDR) is derived from the diabetic retinopathy severity scale (DRSS) as assessed by the central reading center (CRC) using 7-field color fundus photography image. The DRSS on the original score with scores varying from 10 (DR absent) to 85 (very advanced PDR) were then converted into a 12-level scale (Range is from 1 - diabetic retinopathy (DR) absent, to 12- very advanced PDR). (A lower score represents a better outcome.) The event of "No PDR" is then defined as DRSS (12-level scale) \< 7.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 54 for the Study Eye | 187 | 65 |
Proliferative diabetic retinopathy (PDR) is derived from the diabetic retinopathy severity scale (DRSS) as assessed by the central reading center (CRC) using 7-field color fundus photography image. The DRSS on the original score with scores varying from 10 (DR absent) to 85 (very advanced PDR) were then converted into a 12-level scale (Range is from 1 - diabetic retinopathy (DR) absent, to 12- very advanced PDR). (A lower score represents a better outcome.) The event of "No PDR" is then defined as DRSS (12-level scale) \< 7.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 96 for the Study Eye | 188 | 86 |
Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center. PRP = Panretinal photocoagulation laser
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 54 for the Study Eye | 108 | 248 |
Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center. PRP = Panretinal photocoagulation laser
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 96 for the Study Eye | 126 | 262 |
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of \>= 34 ETDRS letters (Snellen equivalent 20/200) at Screening / Baseline in the study eye were included. Min and max possible scores are 0-100 respectively. A higher score represents better functioning. Last observation carried forward (LOCF) was used for the imputation of missing values. The AUC in change from Baseline in BCVA up to Week 54 (or Week 96) is referred to as the averaged change from Baseline in BCVA at each visit up to 54 (or Week 96), which was calculated as (BCVA at Week 6 + BCVA at Week 12 + ... + BCVA at Week 54 (or Week 96)) / number of visits with valid BCVA data from Week 6 to Week 54 (or Week 96) - BCVA at Baseline.
| Letters read | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| up to Week 54 | 0.5 (-0.4 to 1.4) | -3.2 (-4.2 to -2.3) |
| up to Week 96 | -0.1 (-1.2 to 1.1) | -4.3 (-5.4 to -3.1) |
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Week 54 (n=282, 279) | 128 | 57 |
| Week 96 (n=295, 289) | 123 | 65 |
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Week 54 (n=225,220) | 6 | 31 |
| Week 96 (n=236, 201) | 18 | 27 |
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Week 54 (n=282, 279) | 58 | 30 |
| Week 96 (n=295, 289) | 49 | 33 |
Severity of Diabetic retinopathy was evaluated using the ETDRS DRSS score assessed by the Central Reading Center based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on the original scale with scores varying from 10 (DR absent) to 85 (very advanced PDR). All DRSS values were then converted into a 12-level scale, allowing the derivation of the ≥2-step and ≥3-step change from baseline for each post-baseline assessment". A lower score represents better functioning.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Week 54 (n=225, 220) | 4 | 16 |
| Week 96 (n=236, 201) | 11 | 16 |
The vision-threatening complications associated with Diabetic retinopathy (DR) are defined as any event of the following list occurring in the study eye at any time point after Baseline: * Center-involved Diabetic macular edema (CI-DME) as defined as Central sub-field thickness (CSFT) ≥280 µm according to Central reading center (CRC) evaluation of Optical coherent tomography (OCT) image * Retinal detachment * Vitreous hemorrhage * Neovascular glaucoma, iris/ anterior chamber angle neovascularization * Vitrectomy for DR complications
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| up to Week 54 | 117 | 258 |
| up to Week 96 | 144 | 270 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. AEs that started after alternative diabetic retinopathy treatment/relevant diabetic macular edema treatment in the study eye are censored.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Number of subjects with at least one AE | 152 | 199 |
| -Vitreous hemorrhage | 38 | 83 |
| -Cataract | 26 | 27 |
| -Dry eye | 15 | 8 |
| -Intraocular pressure increased | 12 | 3 |
| -Conjunctival hemorrhage | 10 | 5 |
| -Macular oedema | 9 | 34 |
| -Vitreous floaters | 9 | 9 |
| -Conjunctivitis | 7 | 4 |
| -Diabetic retinal oedema | 7 | 36 |
| -Retinal hemorrhage | 5 | 12 |
| -Diabetic retinopathy | 4 | 13 |
| -Eye pain | 3 | 7 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. AEs that started after alternative diabetic retinopathy treatment/relevant diabetic macular edema treatment in the study eye are censored.
| Participants | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm |
|---|---|---|
| Number of subjects with at least one AE | 226 | 217 |
| COVID-19 | 44 | 47 |
| Hypertension | 35 | 24 |
| Upper respiratory tract infection | 28 | 16 |
| Nasopharyngitis | 22 | 16 |
| Anaemia | 15 | 15 |
| Cough | 15 | 10 |
| Pyrexia | 15 | 7 |
| Hyperglycaemia | 13 | 10 |
| Hyperkalaemia | 12 | 2 |
| Urinary tract infection | 12 | 13 |
| Diabetes mellitus | 10 | 5 |
| Pneumonia | 10 | 4 |
| Coronary artery disease | 9 | 5 |
| Hyperlipidaemia | 9 | 8 |
| Hyperuricaemia | 9 | 4 |
| Chronic kidney disease | 8 | 5 |
| Depression | 8 | 3 |
| Blood glucose increased | 7 | 5 |
| Hypercholesterolaemia | 7 | 5 |
| Nausea | 7 | 6 |
| Type 2 diabetes mellitus | 7 | 6 |
| Arthralgia | 5 | 7 |
| Influenza | 5 | 8 |
| -Vomiting | 5 | 9 |
| Diabetic neuropathy | 2 | 10 |
| Diabetic foot | 1 | 7 |
On-treatment deaths are reported from first dose of study treatment until end of study treatment at the time of the interim analysis, plus 4 weeks post treatment, up to a maximum timeframe of approximately 96 weeks. Post-treatment deaths are reported for the timeframe of greater than 30 days after last treatment, also up to Week 96. All deaths refer to the sum of on-treatment and post-treatment deaths.
Results for this outcome have not been posted.
Collected over Adverse events are reported from first dose of study treatment up to Week 90, plus approximately 6 weeks post-treatment, up to a maximum timeframe of approximately 96 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brolucizumab 6mg | 8/347 (2.3%) | 96/347 (27.7%) | 241/347 (69.5%) |
| Panretinal Photocoagulation Laser Arm | 9/342 (2.6%) | 105/342 (30.7%) | 254/342 (74.3%) |
| Overall | 17/689 (2.5%) | 201/689 (29.2%) | 495/689 (71.8%) |
| Event | Brolucizumab 6mg | Panretinal Photocoagulation Laser Arm | Overall |
|---|---|---|---|
| Vitreous haemorrhage - Study eyeEye disorders | 4/347 | 19/342 | 23/689 |
| Vitreous haemorrhage - Fellow eyeEye disorders | 14/347 | 9/342 | 23/689 |
| Cerebral infarctionNervous system disorders | 5/347 | 1/342 | 6/689 |
| HypertensionVascular disorders | 5/347 | 1/342 | 6/689 |
| Acute myocardial infarctionCardiac disorders | 0/347 | 4/342 | 4/689 |
| Myocardial infarctionCardiac disorders | 1/347 | 4/342 | 5/689 |
| Cataract - Study eyeEye disorders | 1/347 | 4/342 | 5/689 |
| Chronic kidney diseaseRenal and urinary disorders | 1/347 | 4/342 | 5/689 |
| Diabetic footSkin and subcutaneous tissue disorders | 0/347 | 4/342 | 4/689 |
| PneumoniaInfections and infestations | 4/347 | 1/342 | 5/689 |
| Event | Brolucizumab 6mg | Panretinal Photocoagulation Laser Arm | Overall |
|---|---|---|---|
| Vitreous haemorrhage - Study eyeEye disorders | 40/347 | 78/342 | 118/689 |
| COVID-19Infections and infestations | 44/347 | 53/342 | 97/689 |
| Vitreous haemorrhage - Fellow eyeEye disorders | 35/347 | 48/342 | 83/689 |
| Diabetic retinal oedema - Study eyeEye disorders | 8/347 | 41/342 | 49/689 |
| Macular oedema - Study eyeEye disorders | 9/347 | 34/342 | 43/689 |
| HypertensionVascular disorders | 31/347 | 29/342 | 60/689 |
| Upper respiratory tract infectionInfections and infestations | 30/347 | 18/342 | 48/689 |
| Cataract - Study eyeEye disorders | 26/347 | 29/342 | 55/689 |
| Cataract - Fellow eyeEye disorders | 22/347 | 28/342 | 50/689 |
| NasopharyngitisInfections and infestations | 22/347 | 17/342 | 39/689 |
| Age, Continuous(Years) | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm | Total |
|---|---|---|---|
| Mean | 53.2 ± 11.88 | 54.7 ± 10.83 | 53.9 ± 11.39 |
| Sex: Female, Male(Participants) | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm | Total |
|---|---|---|---|
| Female | 144 | 132 | 276 |
| Male | 203 | 210 | 413 |
| Race (NIH/OMB)(Participants) | Brolucizumab 6 mg | Panretinal Photocoagulation Laser Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 157 | 148 | 305 |
| Native Hawaiian or Other Pacific Islander | 1 | 4 | 5 |
| Black or African American | 22 | 16 | 38 |
| White | 166 | 169 | 335 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
Showing the first 100 of 120 sites across 16 countries.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals